Comparison of HIV Type 1 ADA gp120 Monomers versus gp140 Trimers as Immunogens for the Induction of Neutralizing Antibodies-Reference-Cited by-同舟云学术

Comparison of HIV Type 1 ADA gp120 Monomers versus gp140 Trimers as Immunogens for the Induction of Neutralizing Antibodies

Published:2005-01 Issue:1 Volume:21 Page:58-67
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Kim Mikyung¹,Qiao Zhi-Song¹,Montefiori David C.²,Haynes Barton F.³,Reinherz Ellis L.¹,Liao Hua-Xin³

Affiliation:

1. Laboratory of Immunobiology and Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115.

2. Department of Surgery, and Human Vaccine Institute, Duke University Medicine Center, Durham, North Carolina 27710.

3. Department of Medicine, and Human Vaccine Institute, Duke University Medicine Center, Durham, North Carolina 27710.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2005.21.58

Reference90 articles.

1. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?

2. HIV-1 antibody — debris or virion?

3. GP120: Biologic Aspects of Structural Features

4. Why do we not have an HIV vaccine and how can we make one?

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies;Vaccines;2020-04-07

2. Critical design criteria for engineering a nanoparticulate HIV-1 vaccine;Journal of Controlled Release;2020-01

3. Use of a Novel Enhanced DNA Vaccine Vector for Preclinical Virus Vaccine Investigation;Vaccines;2019-06-13

4. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus;Journal of Virology;2019-04-15

5. Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens;PLOS ONE;2019-04-10